Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Teva Launches Generic Lovaza Capsules in the U.S. - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

Teva Launches Generic Lovaza Capsules in the U.S.

By: Lisa Olivo

, Rodman Media

A generic equivalent of Lovaza (Omega-3-Acid Ethyl Esters Capsules, USP), has been approved in the U.S. In a statement from Teva Pharmaceutical Industries Ltd., Jerusalem, Israel, the company believes it is first-to-file and thus far is the only company to receive an approval from FDA. It plans to commence shipping immediately.
 
Lovaza Capsules, marketed by GlaxoSmithKline, had annual sales of approximately $1.1 billion in the U.S., according to IMS data as of December 2013.
 
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Teva is the world’s leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in approximately 60 countries. Its branded businesses focus on CNS, oncology, pain, respiratory and women’s health therapeutic areas as well as biologics.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters